LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 29 filers reported holding LYRA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,316,350 | -4.9% | 592,417 | 0.0% | 0.21% | -21.0% |
| Q2 2023 | $2,434,834 | +104.5% | 592,417 | 0.0% | 0.27% | +120.3% |
| Q1 2023 | $1,190,758 | -36.0% | 592,417 | 0.0% | 0.12% | -53.9% |
| Q4 2022 | $1,860,189 | -37.3% | 592,417 | 0.0% | 0.27% | -33.7% |
| Q3 2022 | $2,968,000 | -11.3% | 592,417 | 0.0% | 0.40% | -22.8% |
| Q2 2022 | $3,347,000 | +7506.8% | 592,417 | +5824.2% | 0.52% | +12950.0% |
| Q4 2021 | $44,000 | -97.8% | 10,000 | -95.4% | 0.00% | -98.7% |
| Q3 2021 | $1,967,000 | +33.8% | 215,576 | +17.8% | 0.31% | +35.8% |
| Q2 2021 | $1,470,000 | -73.3% | 183,076 | -61.5% | 0.23% | -77.3% |
| Q1 2021 | $5,515,000 | +6.1% | 475,814 | +4.3% | 0.99% | +44.9% |
| Q4 2020 | $5,199,000 | +320.3% | 456,138 | +312.2% | 0.69% | +4.6% |
| Q3 2020 | $1,237,000 | +80.1% | 110,670 | +82.4% | 0.66% | +67.3% |
| Q2 2020 | $687,000 | – | 60,670 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $3,572,275 | 0.74% |
| Perceptive Advisors | 9,146,730 | $18,384,927 | 0.54% |
| PURA VIDA INVESTMENTS, LLC | 1,996,972 | $4,013,914 | 0.41% |
| VR Adviser, LLC | 924,170 | $1,857,582 | 0.36% |
| Nantahala Capital Management | 2,220,830 | $4,463,868 | 0.34% |
| Ikarian Capital, LLC | 343,685 | $711,427 | 0.16% |
| Soleus Capital Management, L.P. | 592,417 | $1,190,758 | 0.12% |
| Clearline Capital LP | 119,128 | $239,448 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $303,876 | 0.01% |
| Tower Research Capital LLC (TRC) | 9,972 | $20 | 0.00% |